Home GTx

GTx

acquired
IPO
A biopharmaceutical company

Basic Information

GTx is committed to developing novel targeted hormone therapies to provide patients with better medications. GTx focuses on the development of small molecules that selectively modulate the effects of certain hormones produced by the body. The company develops Selective Androgen Receptor Modulators, also known as SARMs, for the potential treatment of a variety of diseases.
GTx, Inc.
Memphis,Tennessee,United States of America
51~100 people
January 01, 1997
investor.relations@gtxinc.com